PRESS RELEASE: Dubai International Capital's Global Strategic Equities Fund appoints advisory board

Dubai International Capital's Global Strategic Equities Fund appoints advisory board

The $2bn Global Strategic Equities Fund (GSEF) founded and sponsored by Dubai International Capital LLC (DIC), the international investment arm of Dubai Holding, today announces that it has formed an advisory board of global business leaders.
The board will be chaired by DIC's Executive Chairman and Chief Executive Officer, Sameer Al Ansari.

GSEF board appointees joining with immediate effect include:

Nobuyuki Idei
Chairman of the Advisory Board and Former Group CEO, Sony Corporation,

Founder and Chief Executive Officer, Quantum Leaps Corporation

Helmut Panke
Former Chief Executive and Chairman of the Management Board, BMW

Joining in 2008:

Jean-Pierre Garnier
Chief Executive Officer (until end of May 2008), GlaxoSmithKline

Sameer Al Ansari, Executive Chairman and CEO of DIC said: ''These are three very substantial appointments for GSEF which reflect the global ambitions of the fund. All three have unrivalled experience in running blue-chip, worldwide businesses, and their industry expertise and international outlook will provide the fund with valuable insights. These appointments come at an exciting time for the GSEF, which has made substantial investments this year in Sony, EADS, and HSBC, and has further large investments planned. I look forward to working with them in developing and diversifying the investment portfolio.'

GSEF recently made a substantial investment in Sony Corporation ('Sony'), one of the world's premier consumer electronics and entertainment companies. In July, GSEF acquired 3.12% of the European aerospace and defence company EADS N.V., making GSEF one of its largest institutional shareholders. In May, it made a substantial investment in HSBC Holdings plc, becoming one of the leading shareholders in the global financial services firm.

All three investments are part of GSEF's mandate to invest in global Fortune 500 companies following the closing of its first round of fundraising efforts at US$1 billion in February 2007. The fund seeks to become a leading shareholder in pre-eminent global large capitalisation stocks, whilst aiming to create value through long-term exposure to a concentrated portfolio of undervalued companies. GSEF is promoted by DIC Asset Management ('DICAM'), the asset management subsidiary of DIC. Its wholly-owned subsidiary, NewDawn GSE Asset Management Limited, is the General Partner for GSEF.

Arab-Asian Investment Conference, Dubai, 3-4 December 2007

Sony will be among the 14 major Asian multinationals participating at DIC's Arab-Asian Investment Conference which will take place in Dubai on 3 and 4 December.

The senior management of the Asian businesses attending the conference will have an opportunity to showcase their companies to a group of more than 100 Arab investors comprising leading regional institutions and high net worth individuals.

The Arab-Asian Investment Conference is sponsored by Daiwa Securities SMBC, Goldman Sachs International, JPMorgan Chase Bank, Natixis Corporate Solutions and UBS Investment Bank.

The impressive line-up of Asia's leading multinational companies that will attend the Conference include Aluminum Corporation of China Ltd (CHALCO), Bharti Airtel Ltd, CITIC Pacific Ltd, Daiwa Securities Group Inc, DBS Group Holdings Ltd, DLF Ltd, Hong Leong Financial Group Bhd, Hyundai Motor Company, ICICI Bank Ltd, Infosys Technologies Ltd, Korea Electric Power Corporation (KEPCO), Samsung Electronics Company, Singapore Telecommunications Ltd and Sony Corporation.

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.